Drugs / mRNA-1443
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03382405 | Nov 2017 → Oct 2020 | cytomegalovirus infection | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1443 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03382405 ↗ |
| Modality | Vaccine | “Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults” NCT03382405 ↗ |